AI News NQ Analysis

"Towards a World Where You Can See a New You" - TOMOCLOUD Achieves Daily Care with Unique Bio-imaging.

NQ Score 50/100

AI Summary (NQ-processed)

TOMOCLOUD, a venture from Chiba University, aims to improve the QOL of lymphedema patients and cancer survivors through its unique bio-imaging technology (EIT), and to develop it into a new platform connecting medical care, nursing care, and healthcare. This press release is TOMOCLOUD's April Dream.

AI analysis data is not yet available.

Frequently Asked Questions

Q: What is TOMOCLOUD's core technology?
A: TOMOCLOUD's core technology is "Electrical Impedance Tomography (EIT)," which captures changes in the electrical properties of the human body to non-invasively visualize the inside of the body.
Q: What problems does this technology solve?
A: It addresses the "unseen anxiety" experienced by lymphedema patients and cancer survivors, contributing to improved QOL by providing easy and accurate bio-information.
Q: What is TOMOCLOUD's ultimate dream?
A: To nurture Japan's EIT technology into a global social model and build a platform that serves as a common language connecting medical care, nursing care, and healthcare from prevention to prognosis.